Xiaowei Chang
Direttore/Membro del Consiglio presso AMBRX INC
Profilo
Xiaowei Chang is currently the Director at Ambrx, Inc. and the Managing Director-Healthcare Investment at Hopu Investments Co. Ltd.
He previously served as an Independent Director at Ambrx Biopharma Cayman, Inc. from 2015 to 2023 and as a Senior Associate at China International Capital Corp.
Ltd.
(Private Equity) from 2011 to 2014.
Mr. Chang received his undergraduate and graduate degrees from Tsinghua University.
Posizioni attive di Xiaowei Chang
| Società | Posizione | Inizio |
|---|---|---|
| AMBRX INC | Direttore/Membro del Consiglio | 01/06/2015 |
Hopu Investments Co. Ltd.
 Hopu Investments Co. Ltd. Financial ConglomeratesFinance Hopu Investments Co. Ltd. functions as an investment holding Caymanian company. | Corporate Officer/Principal | 01/01/2014 |
Precedenti posizioni note di Xiaowei Chang
| Società | Posizione | Fine |
|---|---|---|
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Direttore/Membro del Consiglio | 06/10/2023 |
| China International Capital Corp. Ltd. (Private Equity) | Corporate Officer/Principal | 01/01/2014 |
Formazione di Xiaowei Chang
| Tsinghua University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
| China International Capital Corp. Ltd. (Private Equity) | Finance |
Hopu Investments Co. Ltd.
Hopu Investments Co. Ltd. Financial ConglomeratesFinance Hopu Investments Co. Ltd. functions as an investment holding Caymanian company. | Finance |
- Borsa valori
- Insiders
- Xiaowei Chang
